Day One Biopharmaceuticals Inc (DAWN) concluded trading on Thursday at a closing price of $6.8, with 0.45 million shares of worth about $3.03 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.95% during that period and on July 03, 2025 the price saw a gain of about 1.04%. Currently the company’s common shares owned by public are about 101.35M shares, out of which, 74.66M shares are available for trading.
Stock saw a price change of 4.94% in past 5 days and over the past one month there was a price change of -2.58%. Year-to-date (YTD), DAWN shares are showing a performance of -49.93% which decreased to -46.33% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.08 but also hit the highest price of $16.76 during that period. The average intraday trading volume for Day One Biopharmaceuticals Inc shares is 1.37 million. The stock is currently trading 2.13% above its 20-day simple moving average (SMA20), while that difference is up 0.36% for SMA50 and it goes to -36.41% lower than SMA200.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) currently have 101.35M outstanding shares and institutions hold larger chunk of about 84.18% of that.
The stock has a current market capitalization of $689.26M and its 3Y-monthly beta is at -1.27. It has posted earnings per share of -$0.67 in the same period. It has Quick Ratio of 10.55 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DAWN, volatility over the week remained 3.53% while standing at 4.07% over the month.
Stock’s fiscal year EPS is expected to drop by -35.23% while it is estimated to increase by 39.36% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on October 09, 2024 offering a Buy rating for the stock and assigned a target price range of between $32 and $33 to it. Coverage by BofA Securities stated Day One Biopharmaceuticals Inc (DAWN) stock as a Buy in their note to investors on August 01, 2024, suggesting a price target of $24 for the stock. On April 24, 2024, Needham Reiterated their recommendations, while on April 25, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $9. Stock get an Overweight rating from CapitalOne on February 08, 2023.
